Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voretigene neparvovec-rzyl Re-Administration in LCA
NCT01208389Phase 2Active, not recruiting
- Sponsor
- Spark Therapeutics
- Start
- Nov 2010
- Primary completion
- Oct 2027
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of voretigene neparvovec in Leber congenital amaurosis (LCA), sponsored by Spark Therapeutics. Started Nov 2010; status: active, not recruiting.
02
Drugs
voretigene neparvovec
03
Conditions
Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NCT01208389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01208389.